10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2
QGEN - Qiagen N.V.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$42.51
DETAILS
HIGH:
$48.00
LOW:
$38.60
MEDIAN:
$42.50
CONSENSUS:
$42.51
DOWNSIDE:
1.39%
Stock News
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and.
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corpor.
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGEN's U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is availa.
Understanding Qiagen (QGEN) Reliance on International Revenue
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Qiagen Q2 Earnings Call Highlights
Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates.
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.63 per share a year ago.
Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per share exceeding the outlook while maintaining a high level of profitability. Net sales for Q2 2026 were unchanged at $535 million on a reported basis and at constant exchange rates (CER) compared to Q2 2025, exceeding the outlook for an approximately 2% CER decline. QIAGEN's growth pillars together delivered 5% CER gro.
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allspring Global Investments Holdings LLC Has $100.21 Million Position in Qiagen N.V. $QGEN
Allspring Global Investments Holdings LLC lessened its holdings in shares of Qiagen N.V. (NYSE: QGEN) by 21.6% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 2,481,645 shares of the company's stock after selling 683,160 shares during the period. Allspring Global Investments Holdings LLC owned 1.20%
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis,.
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click her.
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe. The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It comp.
Qiagen: New Launches Signal A Turnaround
Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation.
Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports
Qiagen is drawing early takeover interest from buyout firms, including EQT AB , Advent and KKR , Bloomberg News said on Thursday, citing people familiar with the matter.
Qiagen N.V. (QGEN) Shareholder/Analyst Call Transcript
Qiagen N.V. (QGEN) Shareholder/Analyst Call Transcript
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
Price Targets
Qiagen price target raised to $40 from $36 at Stifel
$40.00
(was $42.06)
Daniel Arias
·
Stifel Nicolaus
Qiagen price target raised to $40 from $38 at Barclays
$40.00
(was $41.73)
Barclays
Qiagen price target raised to $48 from $46 at Jefferies
$48.00
(was $41.73)
Jefferies
Qiagen downgraded to Hold from Buy at Berenberg
$45.50
(was $41.44)
Harry Gillis
·
Berenberg Bank
Qiagen initiated with a Hold at Kepler Cheuvreux
$38.60
(was $38.73)
Kepler Capital
Qiagen upgraded to Overweight from Equal Weight at Morgan Stanley
$42.00
(was $36.28)
Morgan Stanley
Qiagen price target lowered to $36 from $50 at Stifel
$36.00
(was $32.98)
Stifel Nicolaus
Qiagen price target lowered to $43 from $54 at Deutsche Bank
$43.00
(was $33.89)
Jan Koch
·
Deutsche Bank
Qiagen price target lowered to $38 from $44 at Barclays
$38.00
(was $34.02)
Luke Sergott
·
Barclays
Qiagen upgraded to Outperform from Neutral at Baird
$43.00
(was $34.02)
Robert W. Baird
Qiagen downgraded to Equal Weight from Overweight at Barclays
$44.00
(was $41.91)
Barclays
Qiagen price target raised to $52 from $50 at UBS
$52.00
(was $50.95)
UBS
Qiagen price target raised to $53 from $48.42 at Baird
$53.00
(was $51.17)
Cathy Ramsey Schulte
·
Robert W. Baird
Qiagen price target raised to $50 from $45 at Stifel
$50.00
(was $51.25)
Stifel Nicolaus
Qiagen price target raised to $58 from $55 at Barclays
$58.00
(was $51.23)
Barclays
Qiagen price target raised to $59 from $57 at Jefferies
$59.00
(was $51.23)
Jefferies
Deutsche Bank Downgrades Qiagen NV (QGEN) to Hold
$54.00
(was $55.66)
Jan Koch
·
Deutsche Bank
Qiagen price target raised to $55 from $53 at Barclays
$55.00
(was $47.64)
Barclays
Qiagen price target lowered to $53 from $55 at Barclays
$53.00
(was $48.76)
Catherine Ramsey Schulte
·
Barclays
Qiagen downgraded to Hold from Buy at HSBC
$49.00
(was $45.48)
Shubhangi Gupt
·
HSBC